Robert Roberts1. 1. University of Arizona College of Medicine-Phoenix, 550 East Van Buren, Phoenix, AZ, 85004, USA. rroberts2@email.arizona.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this study is to review genetic risk variants for coronary artery disease (CAD) and how they will change the management and prevention of CAD currently and in the future. RECENT FINDINGS: Through the efforts of international consortia, 58 genetic risk variants for CAD of genome-wide significance have been replicated in appropriate independent populations. Only one third of these variants mediate their risk through known conventional risk factors for CAD. Thus, unknown mechanisms contribute to CAD. Secondly, the genetic risk is proportional to the total number of risk variants rather than the intensity of any risk factor. Thirdly, the availability of the genetic risk variants enables one to perform Mendelian randomization (MR) studies since they are randomized at conception, not confounded, fixed for life, and can be used to determine if a risk factor is causative or just a marker. MR can also be used to determine the safety and efficacy of a gene product targeted for drug therapy. Genetic risk variants have been shown to successfully risk stratify for CAD in both primary and secondary preventions. Contrary to dogma, MR documents that plasma HDL-C is not protective of CAD. The use of genetic risk score (GRS) for CAD is shown to be more effective in risk stratifying for CAD than the Framingham risk score and independent of the conventional risk factors including family history. Furthermore, the GRS predicts the response to statin therapy in primary and secondary preventions. The use of GRS could represent a paradigm shift in the prevention of CAD.
PURPOSE OF REVIEW: The purpose of this study is to review genetic risk variants for coronary artery disease (CAD) and how they will change the management and prevention of CAD currently and in the future. RECENT FINDINGS: Through the efforts of international consortia, 58 genetic risk variants for CAD of genome-wide significance have been replicated in appropriate independent populations. Only one third of these variants mediate their risk through known conventional risk factors for CAD. Thus, unknown mechanisms contribute to CAD. Secondly, the genetic risk is proportional to the total number of risk variants rather than the intensity of any risk factor. Thirdly, the availability of the genetic risk variants enables one to perform Mendelian randomization (MR) studies since they are randomized at conception, not confounded, fixed for life, and can be used to determine if a risk factor is causative or just a marker. MR can also be used to determine the safety and efficacy of a gene product targeted for drug therapy. Genetic risk variants have been shown to successfully risk stratify for CAD in both primary and secondary preventions. Contrary to dogma, MR documents that plasma HDL-C is not protective of CAD. The use of genetic risk score (GRS) for CAD is shown to be more effective in risk stratifying for CAD than the Framingham risk score and independent of the conventional risk factors including family history. Furthermore, the GRS predicts the response to statin therapy in primary and secondary preventions. The use of GRS could represent a paradigm shift in the prevention of CAD.
Entities:
Keywords:
Coronary artery disease; Genetic risk score for CAD; Genetic risk stratifications for CAD; Genetics; Mendelian randomization
Authors: William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub Journal: N Engl J Med Date: 2011-11-15 Impact factor: 91.245
Authors: Paul S de Vries; Maryam Kavousi; Symen Ligthart; André G Uitterlinden; Albert Hofman; Oscar H Franco; Abbas Dehghan Journal: Int J Epidemiol Date: 2015-05-06 Impact factor: 7.196
Authors: Heribert Schunkert; Inke R König; Sekar Kathiresan; Muredach P Reilly; Themistocles L Assimes; Hilma Holm; Michael Preuss; Alexandre F R Stewart; Maja Barbalic; Christian Gieger; Devin Absher; Zouhair Aherrahrou; Hooman Allayee; David Altshuler; Sonia S Anand; Karl Andersen; Jeffrey L Anderson; Diego Ardissino; Stephen G Ball; Anthony J Balmforth; Timothy A Barnes; Diane M Becker; Lewis C Becker; Klaus Berger; Joshua C Bis; S Matthijs Boekholdt; Eric Boerwinkle; Peter S Braund; Morris J Brown; Mary Susan Burnett; Ian Buysschaert; John F Carlquist; Li Chen; Sven Cichon; Veryan Codd; Robert W Davies; George Dedoussis; Abbas Dehghan; Serkalem Demissie; Joseph M Devaney; Patrick Diemert; Ron Do; Angela Doering; Sandra Eifert; Nour Eddine El Mokhtari; Stephen G Ellis; Roberto Elosua; James C Engert; Stephen E Epstein; Ulf de Faire; Marcus Fischer; Aaron R Folsom; Jennifer Freyer; Bruna Gigante; Domenico Girelli; Solveig Gretarsdottir; Vilmundur Gudnason; Jeffrey R Gulcher; Eran Halperin; Naomi Hammond; Stanley L Hazen; Albert Hofman; Benjamin D Horne; Thomas Illig; Carlos Iribarren; Gregory T Jones; J Wouter Jukema; Michael A Kaiser; Lee M Kaplan; John J P Kastelein; Kay-Tee Khaw; Joshua W Knowles; Genovefa Kolovou; Augustine Kong; Reijo Laaksonen; Diether Lambrechts; Karin Leander; Guillaume Lettre; Mingyao Li; Wolfgang Lieb; Christina Loley; Andrew J Lotery; Pier M Mannucci; Seraya Maouche; Nicola Martinelli; Pascal P McKeown; Christa Meisinger; Thomas Meitinger; Olle Melander; Pier Angelica Merlini; Vincent Mooser; Thomas Morgan; Thomas W Mühleisen; Joseph B Muhlestein; Thomas Münzel; Kiran Musunuru; Janja Nahrstaedt; Christopher P Nelson; Markus M Nöthen; Oliviero Olivieri; Riyaz S Patel; Chris C Patterson; Annette Peters; Flora Peyvandi; Liming Qu; Arshed A Quyyumi; Daniel J Rader; Loukianos S Rallidis; Catherine Rice; Frits R Rosendaal; Diana Rubin; Veikko Salomaa; M Lourdes Sampietro; Manj S Sandhu; Eric Schadt; Arne Schäfer; Arne Schillert; Stefan Schreiber; Jürgen Schrezenmeir; Stephen M Schwartz; David S Siscovick; Mohan Sivananthan; Suthesh Sivapalaratnam; Albert Smith; Tamara B Smith; Jaapjan D Snoep; Nicole Soranzo; John A Spertus; Klaus Stark; Kathy Stirrups; Monika Stoll; W H Wilson Tang; Stephanie Tennstedt; Gudmundur Thorgeirsson; Gudmar Thorleifsson; Maciej Tomaszewski; Andre G Uitterlinden; Andre M van Rij; Benjamin F Voight; Nick J Wareham; George A Wells; H-Erich Wichmann; Philipp S Wild; Christina Willenborg; Jaqueline C M Witteman; Benjamin J Wright; Shu Ye; Tanja Zeller; Andreas Ziegler; Francois Cambien; Alison H Goodall; L Adrienne Cupples; Thomas Quertermous; Winfried März; Christian Hengstenberg; Stefan Blankenberg; Willem H Ouwehand; Alistair S Hall; Panos Deloukas; John R Thompson; Kari Stefansson; Robert Roberts; Unnur Thorsteinsdottir; Christopher J O'Donnell; Ruth McPherson; Jeanette Erdmann; Nilesh J Samani Journal: Nat Genet Date: 2011-03-06 Impact factor: 38.330
Authors: J L Mega; N O Stitziel; S Kathiresan; M S Sabatine; J G Smith; D I Chasman; M Caulfield; J J Devlin; F Nordio; C Hyde; C P Cannon; F Sacks; N Poulter; P Sever; P M Ridker; E Braunwald; O Melander Journal: Lancet Date: 2015-03-04 Impact factor: 79.321